Asian Journal of Pharmaceutical Sciences    2009, 4(1): 56-64   ISSN: 1818-0876   CN:    

 
Information & service
This article
 Supporting info
 PDF (0KB)
 [Full HTML] (0KB)
 Reference [PDF]
 Reference
Service and feedback
Email this page
 Add to bookshelf
 Add to citation manager
 Cite this paper
 Email Alert
Relative Information
  Other article of author
Enhanced oral bioavailability of Astragaloside IV in rats through
complexation with 2-hydroxypropyl-beta-cyclodextrin
Zhenhua Chen, Bing Gu*
School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, China
Received 2008-5-12 ; Revised 2008-8-29 ; Accepted 2008-11-24 ; Online 2009-3-10

Abstract

Purpose: Astragaloside IV (AGS-IV), the main active constituent of the Chinese medical herb, Astragalus membranaceus, is reported to exhibit a variety of cardiovascular pharmacological actions. However its poor aqueous solubility affects its oral absorption which limits its development as a treatment and its preclinical investigation. The effect of 2-hydroxypropyl-beta-cyclodextrin (HPCD), a novel solubility enhancer, on the oral bioavailability of AGS-IV in Sprague Dawley rats was evaluated with the aim of preparing a stable and effective oral formulation suitable for clinical application. Methods: Inclusion compounds in aqueous solution were prepared by solution-agitating technique, and identified by observation under a microscope, differential scanning calorimetry, solubility and phase solubility diagrams. The concentrations of AGS-IV in rat plasma were determined by liquid chromatograph-mass spectrometry/mass spectrometry. Results: Both methods involving novel optical rotation continuous variation plotting and the analysis of phase solubility diagrams consistently proved that AGS-IV and HPCD can form an inclusion compound with a molar ratio of 1: 1. The solubility of AGS-IV in neutral aqueous solution at 25˚C was increased from 22.2 µg/ml to 286.8 µg/ml. The concentration-time profiles in plasma samples after oral administration of AGS-IV and the inclusion compound both fitted a two-compartment model. The t1/2 of the inclusion compound was 12.88 h, and the AUC was 5275.49 ng·h/ml, whereas the t1/2 of AGS-IV was 4.54 h, and the AUC was 1184.32 ng·h/ml. Conclusion: Complexation with HPCD can significantly increase AGS-IV oral bioavailability in rats, reducing the variability in its systemic concentration and pharmacological effects. The continuous variation plot based on the optical rotation increment is a reliable addition to the classical continuous variation method used widely in the pharmaceutical sciences.


Keywords:  Astragaloside IV   2-hydroxypropyl-beta-cyclodextrin   Inclusion compound   Bioavailability   Rats
 

DOI: 

Correponding author: Bing Gu; Email: bguemory@hotmail.com